View Featured Categories
Why Tirzepatide Continues to Outperform in Clinical Trials
Tirzepatide has become one of the most talked-about medications for weight loss and blood sugar management — and clinical trial data keeps explaining why. Unlike traditional GLP-1 medications such as semaglutide, tirzepatide activates two hormone pathways instead of one. That dual mechanism may be the key to its standout performance in head-to-head trials.
How Tirzepatide Works
To understand why tirzepatide may outperform other options, it helps to understand the two hormones it targets.
GLP-1
Glucagon-like peptide-1 is a hormone your body naturally produces. It boosts insulin release when blood sugar rises, slows digestion, and reduces appetite.
GIP
Glucose-dependent insulinotropic polypeptide is another hormone involved in blood sugar and insulin control. Tirzepatide activates both GIP and GLP-1 receptors at once.
Researchers believe these two pathways work together, producing a stronger combined effect on blood sugar control and food intake than targeting GLP-1 alone. The exact contribution of GIP is still being studied, but its dual action is considered central to tirzepatide's results.
Tirzepatide and Weight Loss: The SURMOUNT-5 Trial
The strongest evidence supporting tirzepatide's edge comes from SURMOUNT-5, a clinical trial that directly compared tirzepatide with semaglutide in 751 adults with obesity who did not have type 2 diabetes.
After 72 Weeks
20.2%
average weight loss with tirzepatide
13.7%
average weight loss with semaglutide
Tirzepatide also produced a greater reduction in waist size — about 18.4 centimeters compared with 13.0 centimeters for semaglutide.(1) Waist size matters because it's a key indicator of visceral fat, the fat surrounding internal organs that's linked to higher risks of heart disease, diabetes, and metabolic syndrome.
Because SURMOUNT-5 compared both medications directly in the same trial, the results carry more weight (pardon the pun) than comparing outcomes across two separate studies.
Tirzepatide and Blood Sugar Control
Tirzepatide is also used to improve blood sugar in people with type 2 diabetes. One key measurement is HbA1c, a blood test that estimates average blood sugar over the past 2 to 3 months.
In the SURPASS-1 trial, tirzepatide reduced HbA1c by approximately 1.87% to 2.07% after 40 weeks, depending on dose, alongside significant weight loss.(2) Because excess weight and type 2 diabetes often occur together, a medication that addresses both offers a meaningful advantage.
Why Might Tirzepatide Work So Well?
1. It Works on Two Hormone Pathways
Most traditional GLP-1 medications target only the GLP-1 receptor. Tirzepatide activates both GIP and GLP-1, and the two pathways appear to complement each other for a stronger combined effect on blood sugar and appetite.
2. It Can Reduce Appetite
Tirzepatide can reduce hunger and overall food intake. Sustained reduction in calorie intake over time is a key driver of long-term weight loss success.
3. It Improves Blood Sugar Regulation
Tirzepatide helps the body release insulin when blood sugar rises and can reduce inappropriate glucagon release. Insulin moves glucose from the bloodstream into cells for energy, while glucagon generally raises blood sugar — by affecting both, tirzepatide helps keep levels balanced.
4. Higher Doses Can Produce Greater Weight Loss
The SURMOUNT-1 trial found that average weight loss after 72 weeks increased with dose: about 15.0% at 5 mg, 19.5% at 10 mg, and 20.9% at 15 mg, compared with 3.1% for placebo.(3) Higher doses may also bring more side effects, so the right dose depends on the individual.
Side Effects and Safety
Tirzepatide is powerful, but it isn't free of side effects. The most common involve the digestive system, including nausea, diarrhea, vomiting, constipation, and abdominal discomfort. In SURMOUNT-5, digestive side effects occurred with both tirzepatide and semaglutide, and were mostly mild to moderate, becoming more common at higher doses.(1) That's why doctors typically increase the dose gradually, giving the body time to adjust.
Is Tirzepatide Better Than Every GLP-1 Medication?
The strongest current evidence shows tirzepatide produced greater average weight loss than semaglutide in a direct head-to-head trial.(1) That said, other medications may offer different benefits depending on a patient's health, treatment goals, and medical history — and studies of different medications often use different populations, doses, and durations, so context matters.
Interestingly, real-world data shows up to four times more people switch from semaglutide to tirzepatide than the reverse.(4) If you're just starting a weight loss journey and considering a GLP-1 medication, that pattern is worth factoring into the conversation with your provider.
Key Takeaway
Tirzepatide differs from traditional GLP-1 medications by activating both the GIP and GLP-1 pathways. This dual action may explain its strong results on appetite, weight loss, and blood sugar — and the SURMOUNT-5 trial directly demonstrated greater average weight loss with tirzepatide than semaglutide over 72 weeks.
Still, no single medication is the right fit for every patient. Treatment decisions should weigh side effects, medical history, goals, cost, access, and individual response. Overall, tirzepatide remains one of the most effective incretin-based options currently available for weight management and blood sugar control.
*This content is for informational purposes only and is not intended as medical advice. Individual results vary. Consult your healthcare provider before starting any new medication. This statement has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
Tirzepatide
A daily, no-needle weight loss solution that targets both the GLP-1 and GIP pathways to support weight loss and satiety.
Shop NowYou Might Also Be Interested In
Brooke Lounsbury
TWC Contributor
References
- Aronne, L. J., Bade Horn, D., le Roux, C. W., et al. (2025). Tirzepatide as compared with semaglutide for the treatment of obesity. New England Journal of Medicine, 393(1), 26–36. https://doi.org/10.1056/NEJMoa2416394
- Rosenstock, J., Wysham, C., Frías, J. P., et al. (2021). Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): A double-blind, randomised, phase 3 trial. The Lancet, 398(10295), 143–155. https://doi.org/10.1056/S0140-6736(21)01324-6
- Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038
- Samuels JM, Ye F, Irlmeier R, Silver H, Srivastava G, Spann M. Real-world titration, persistence & weight loss of semaglutide and tirzepatide in an academic obesity clinic. Diabetes Obes Metab. 2025; 27(11): 6200-6209. doi:10.1111/dom.70004
